A recent meta-analysis1,2 and a prospective study3 reported that bacterial coinfection and secondary infection among patients with COVID-19 infection are uncommon. However, in these studies, antimicrobial drugs were prescribed for approximately 70% of patients with the disease.2 Therefore, data are needed on patients with COVID-19 infection who do not routinely receive an antimicrobial drug prescription, to identify the true rate of concurrent infection in this patient population. At the National Hospital Organization Tochigi Medical Center in Utsunomiya, Tochigi, Japan, since the beginning of the COVID-19 pandemic, antimicrobial drugs have not been prescribed for patients with COVID-19 infection unless their symptoms are suggestive of another infectious disease. Therefore, we investigated the prevalence of antimicrobial drug use and concurrent infections among patients with COVID-19 during hospitalization.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: December 30, 2021.
Published: February 18, 2022. doi:10.1001/jamanetworkopen.2022.0040
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Komagamine J et al. JAMA Network Open.
Corresponding Author: Junpei Komagamine, MD, Department of Internal Medicine, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomatsuri, Utsunomiya, Tochigi, Japan (email@example.com).
Author Contributions: Dr Komagamine had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Komagamine, Yabuki.
Acquisition, analysis, or interpretation of data: Komagamine, Matsumoto, Tanaka.
Drafting of the manuscript: Komagamine.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Komagamine.
Supervision: Komagamine, Yabuki.
Conflict of Interest Disclosures: None reported.
Meeting Presentation: Data from this study will be used at a poster presentation at the 119th Annual Meeting of the Japanese Society of Internal Medicine, April 15-17, 2022; virtual.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.